Shenzhen Zhongxing Yangfan Biotech

Shenzhen Zhongxing Yangfan Biotech is a clinical-stage biopharmaceutical company headquartered in Shenzhen, China, specializing in the development of novel small molecule drugs for cancer treatment. The company's primary focus is on targeting cell cycle regulators and other validated oncogenic pathways to create more effective therapies for solid tumors. Its lead candidate, ZYF-101, is a potent and selective CDK4/6 inhibitor currently undergoing clinical evaluation for advanced breast cancer and other solid malignancies. Zhongxing Yangfan integrates drug design, preclinical research, and clinical development to advance its pipeline of innovative oncology assets. The company was established as part of the ZTE Group's strategic expansion into the life sciences sector.